Amid a worsening opioid crisis, a U.S. senator has opened a probe into Alkermes and its controversial promotion of the Vivitrol monthly shot for combating opioid addiction.

The move comes as Alkermes is scrutinized for aggressive lobbying and marketing. The company has spent heavily on contributions to lawmakers who are trying to mitigate opioid abuse. In state legislatures across the country, the drug maker has pushed bills that favor its treatment over rival medicines. And Alkermes has provided thousands of free doses to encourage usage in jails and prisons.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I came to know Dick Pops a few years ago during a proposed merger. Dick is an honorable man. Harris is a naked political opportunist whom I wouldn’t allow to shine his shoes, racial metaphors notwithstanding.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy